Exploring Neuropeptide Y Receptors: Key to Gut Health and Future Therapies

The Neuropeptide Y (NPY) system, comprising NPY and its diverse receptor subtypes (Y1, Y2, Y4, Y5), is a crucial regulator in various physiological processes throughout the body. Within the gastrointestinal tract, NPY plays a significant role in modulating functions such as motility, secretion, and inflammatory responses, impacting conditions like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This review article synthesizes current knowledge to highlight the therapeutic potential of targeting NPY receptors for a range of gut-related disorders.

The review revealed that NPY and its receptors are profoundly involved in regulating fundamental gut processes, including intestinal motility, fluid and electrolyte transport, and the immune response within the gut wall. Activation of Y1 and Y2 receptors often exerts opposing effects on gut transit, with Y1 typically promoting relaxation and Y2 inhibiting it, demonstrating a complex regulatory balance. Furthermore, NPY signaling through Y5 receptors was consistently implicated in appetite regulation and energy homeostasis, suggesting a direct link to metabolic disorders and obesity. Modulators targeting Y2 receptors, for instance, have shown significant potential in reducing colonic inflammation in multiple preclinical models, while Y5 antagonists are being explored for their anti-obesity effects, demonstrating robust efficacy in reducing food intake and body weight in animal studies. The authors identified over a dozen distinct physiological roles for NPY in the gut. The authors concluded that selective modulation of NPY receptor subtypes offers a highly promising strategy for developing novel treatments for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and obesity, by precisely targeting specific gut functions and inflammatory pathways.